Transseptal crossing is used to access the left atrium crossing from the right atrium through the septal wall for any of a variety of electrophysiology (EP) or structural heart procedures. For example, the left atrium is routinely accessed to assess hemodynamics and/or perform mitral valvuloplasty, or to accommodate transvascular atrial fibrillation (AF) ablation procedures.
Crossing the septum normally requires locating and puncturing the fossa ovalis to access the left atrium. Locating the fossa ovalis may be accomplished using fluoroscopy and ultrasound, and potentially echocardiography.
Mechanical puncture through the tissue of the fossa ovalis can be accomplished using a piercing tool such as a standard Brockenbrough needle as is understood in the art. Alternatively, a transseptal needle having a radio frequency energized tip may be used, such as those produced by Baylis Medical Company, Inc.
The foregoing devices and techniques have proven useful in a variety of EP and structural heart procedures, in which the procedural access sheath is often no larger than about 3.667 mm (11 French). However, a growing number of procedures such as left atrial appendage occlusion device implantation and various Mitral valve replacement or repair require “large bore” access, which is not possible using the above techniques alone.
Instead, traditional transseptal puncture is normally carried out with small bore sheaths ranging from 8 Fr to 11 Fr which are then exchanged over stiff guidewires for the large bore sheaths with outer dimensions as large as 24 Fr in the case of the MitraClip Steerable Guide Catheter. Dilators for the transseptal sheaths usually accommodate 0.032 in. wires, however Baylis has introduced a small bore transseptal sheath with a dilator that accommodates a 0.035 in. wire. Regardless of the transseptal sheath, the operator must utilize a number of additional pieces of equipment including the small bore transseptal sheath and dilator, and often a 0.025 in. “stiff” pigtail wire (Baylis, Toray) to use as a rail to drive the small bore transseptal sheath and dilator before switching to a 0.035 in. guidewire (Amplatz extra stiff or Safari) to drive the large bore sheath safely into the LA. The entire small bore sheath must be driven into the LA to make the switch to the appropriate stiff 0.035 in. guidewire to drive the large bore sheath.
Thus, there remains a need for a transseptal crossing system that is based upon a 0.035 inch guidewire access, that enables single pass crossing of larger sheaths, such as the Boston Scientific Watchman guide sheath, Medtronic Flexcath and others known in the art or yet to be released.
In general, the present invention provides a single pass transseptal crossing device, for enabling large bore access in a single pass. The system includes an insulated cannula with a conductive tip positionable through the dilator of a large bore sheath. The tip of the cannula is expressed distal to the tip of the dilator. The insulated cannula can serve as an electrical conduit of RF energy. The cannula can be energized to deliver RF energy directly to tissues and /or through a separate conductive wire or obturator. An insulated wire or obturator can thus be independently energized or can be energized passively via the energized cannula. The cannula may be 0.050″ outer diameter (OD) and approximately 0.038″ inner diameter (ID) allowing delivery of a 0.035″ wire which together (stiff 0.035 wire and 0.050 cannula) creates a sturdy rail to drive large bore dilators and sheaths in a single pass. The tip of the cannula can be scalloped to deliver high density current to the scalloped edges for improved cutting. The system permits irrigation with hypotonic saline or D5W to preferentially drive current through the myocardium.
Thus, there is provided in accordance with one aspect of the present invention a single pass, large bore transseptal crossing catheter, such as for accessing the left atrium of the heart. The catheter comprises an elongate, flexible tubular body, having a proximal end, a distal end and an electrically conductive sidewall defining a central lumen. An insulation layer surrounds the sidewall and leaving exposed a first distal electrode tip. An inner conductive wire having a second distal electrode tip, is axially movably extendable through the central lumen. A tubular insulation layer is provided in between the wire and the electrically conductive sidewall.
The first distal electrode tip may comprise an annular conductive surface at the distal end of the tubular body. The second distal electrode tip may be concentrically extendable through the annular conductive surface. The first distal electrode tip may comprise at least one distal projection, or at least two or three projections and in one implementation comprises a scalloped distal edge.
The second distal electrode may comprise a smooth, hemispherical surface, or may be provided with a sharpened distally facing projection. The catheter may additionally comprise an annular lumen extending between the tubular body and the wire, from the proximal hub to an exit port at the distal end.
In accordance with a further aspect of the present invention, there is provided an introducer sheath, for enabling a single pass, large bore transseptal crossing. The introducer sheath comprises an elongate, flexible tubular body, having a proximal end, a distal end and an electrically conductive sidewall defining a central lumen. A tubular insulation layer may surround the sidewall, leaving exposed an annular conductive surface at the distal end. A proximal hub may be provided on the tubular body, having at least one access port in communication with the central lumen. A connector may be carried by the proximal end, in electrical communication with the conductive sidewall. The distal conductive surface may comprise at least one distal projection, or at least two or three projections and in one implementation comprises a scalloped distal edge.
There is also provided a method of accessing the left atrium with a large bore catheter in a single pass. The method comprises providing a single pass, large bore transseptal crossing catheter; positioning the distal end in contact with a fossa ovalis; and energizing the distal end to enable passage of the distal end into the left atrium.
The energizing step may comprise energizing a first distal electrode tip on a conductive tubular cannula and/or energizing a second distal electrode tip on an RF core wire. The first and second distal electrode tips may be energized in a bipolar mode.
The method may comprise accessing the left atrium, energizing the second distal electrode tip, advancing the wire through the fossa ovalis, thereafter energizing the first distal electrode tip and advancing the cannula into the left atrium.
A large bore access sheath may thereafter be advanced over the transseptal crossing catheter and into the left atrium, and the transseptal crossing catheter may then be removed, leaving the large bore access sheath extending into the left atrium.
An index procedure catheter may be advanced through the large bore access sheath and into the left atrium. The index procedure catheter may be configured to deliver a left atrial appendage implant such as an occlusion device, or to accomplish a mitral valve repair or replacement.
In some embodiments, the tubular body 104 may have at least one lumen extending from proximal region 108 to distal region 106 such as lumen 208 shown in
Distal region 106 comprises a softer polymer material with an optional embedded braid or coil so that it is pliable and atraumatic when advanced through vasculature. In some embodiments, the material is also formable (e.g., Nitinol or stainless steel with a polymer jacket), so that its shape can be changed during manufacturing, typically by exposing it to heat while it is fixed in a desired shape. In an alternate embodiment, the shape of distal region is modifiable by the operator during use. An example of a suitable plastic is PEBAX (a registered trademark of Atofina Chemicals, Inc.). In the present embodiment, the distal region 106 comprises a curve portion 115.
As the distal region 106 is advanced out of a guiding sheath, it may have a preset curve so that it curls away from the general axis of the sheath which helps ensure that energy delivery tip 112 is not in a position to inadvertently injure unwanted areas within a patient's heart after trans-septal perforation. Curve length may be about 4 cm (about 1.57″) to about 6 cm (about 2.36″) and the curve may traverse about 225 to about 315 degrees of the circumference of a circle. For example, the curve may be about 5 cm in length and may traverse about 270 degrees of the circumference of a circle. Such an embodiment may be useful to avoid unwanted damage to cardiac structures.
In some embodiments, curve portion 115 begins about 0.5 cm to about 1.5 cm proximal to energy delivery device 112, leaving an approximately 1 cm (about 0.39″) straight portion in the distal region 106 of apparatus 102. This ensures that this initial portion of apparatus 102 will exit dilator 84 (see
Distal region 106 may have a smaller outer diameter compared to the remainder of tubular body 104 so that dilation of a perforation is limited while the distal region 106 is advanced through the perforation. Limiting dilation seeks to ensure that the perforation will not cause hemodynamic instability once apparatus 102 is removed. In some embodiments, the outer diameter of distal region 106 may be no larger than about 0.8 mm to about 1.0 mm. For example, the outer diameter of distal region 106 may be about 0.9 mm (about 0.035″). This is comparable to the distal outer diameter of the trans-septal needle that is traditionally used for creating a perforation in the atrial septum. Similarly, in some embodiments, the outer diameter of tubular body 104 may be no larger than about 0.040″ to about 0.060″. For example, the outer diameter of tubular body 104 may be about 0.050″ (1.282 mm), which is also comparable to the trans-septal needle dimensions.
Distal region 106 terminates at functional tip region 110, which comprises an energy delivery component and optionally also as an ECG measuring device. Functional tip region 110 comprises at least one energy delivery tip 112 made of a conductive and optionally radiopaque material, such as stainless steel, tungsten, platinum, or another metal. One or more radiopaque markings may be affixed to tubular body 104 to highlight the location of the transition from distal region 106 to the remainder of tubular body 104, or other important landmarks on apparatus 102. Alternately, the entire distal region 106 of apparatus 102 may be radiopaque. This can be achieved by filling the polymer material, for example PEBAX, used to construct distal region 106 with radiopaque filler. An example of suitable radiopaque filler is Bismuth. Distal region 106 may contain at least one opening 109 which is in fluid communication with main lumen 200 (
In the illustrated embodiment, proximal region 108 comprises a hub 114, to which are attached a catheter connector cable 116, and connector 118. Tubing 117 and adapter 119 are attached to hub 114 as well. Proximal region 108 may also have one or more depth markings 113 to indicate distances from functional tip region 110, or other important landmarks on apparatus 102. Hub 114 comprises a curve direction or orientation indicator 111 that is located on the same side of apparatus 102 as the curve 115 in order to indicate the direction of curve 115. Orientation indicator 111 may comprise inks, etching, or other materials that enhance visualization or tactile sensation. One or more curve direction indicators may be used and they may be of any suitable shape and size and a location thereof may be varied about the proximal region 108.
In the illustrated embodiment, adapter 119 is configured to releaseably couple apparatus 102 to an external pressure transducer 121 via external tubing 123. External pressure transducer 121 is coupled to a monitoring system 125 that converts a pressure signal from external pressure transducer 121 and displays pressure as a function of time. Catheter connector cable 116 may connect to an optional Electro-cardiogram (ECG) interface unit via connector 118. An optional ECG connector cable connects an ECG interface unit to an ECG recorder, which displays and captures ECG signals as a function of time. A generator connector cable may connect the ECG interface unit to an energy source such as a generator (not illustrated). In this embodiment, the ECG interface unit can function as a splitter, permitting connection of the electrosurgical tissue piercing apparatus 102 to both an ECG recorder and generator simultaneously. ECG signals can be continuously monitored and recorded and the filtering circuit within the ECG interface unit and may permit energy, for example RF energy, to be delivered from generator 128 through electrosurgical apparatus 102 without compromising the ECG recorder.
In another embodiment (not shown) of apparatus 102, there may be a deflection control mechanism associated with the distal region 106 of apparatus 102 and an operating mechanism to operate said control mechanism associated with the proximal region 108 of apparatus 102. One or two or more pull wires may extend from a proximal control to the distal region 106 to actively deflect the distal region 106 as will be understood in the art. The control mechanism may be used to steer or otherwise actuate at least a portion of distal region 106.
Generator 128 may be a radiofrequency (RF) electrical generator that is designed to work in a high impedance range. Because of the small size of energy delivery tip 112, the impedance encountered during RF energy application is very high. General electrosurgical generators are typically not designed to deliver energy in these impedance ranges, so only certain RF generators can be used with this device. In one embodiment, the energy is delivered as a continuous wave at a frequency between about 400 kHz and about 550 kHz, such as about 460 kHz, a voltage of between 100 to 200 V RMS and a duration of up to 99 seconds. A grounding pad 130 is coupled to generator 128 for attaching to a patient to provide a return path for the RF energy when generator 128 is operated in a monopolar mode.
Other embodiments could use pulsed or non-continuous RF energy. Some embodiments for pulsed radio frequency energy have radio frequency energy of not more than about 60 watts, a voltage from about 200 Vrms to about 400 Vrms and a duty cycle of about 5% to about 50% at about from slightly more than 0 Hz to about 10 Hz. More specific embodiments include radio frequency energy of not more than about 60 watts, a voltage from about 240 Vrms to about 300 Vrms and a duty cycle of 5% to 40% at 1 Hz, with possibly, the pulsed radio frequency energy being delivered for a maximum of 10 seconds. In one example, the generator can be set to provide pulsed radio frequency energy of not more than about 50 watts, a voltage of about 270 Vrms, and a duty cycle of about 10% at 1 Hz. Alternatively, the pulsed radio frequency energy could comprise radio frequency energy of not more than about 50 watts, a voltage of about 270 Vrms, and a duty cycle of about 30% at 1 Hz.
In still other embodiments of apparatus 102, different energy sources may be used, such as radiant (e.g. laser), ultrasound, thermal or other frequencies of electrical energy (e.g. microwave), with appropriate energy sources, coupling devices and delivery devices depending upon the desired clinical performance.
Additional details of the tissue penetration apparatus 102 are described in connection with
Referring to
Referring to
The separately insulated cannula 206 and guidewire can be configured to deliver bipolar electricity to the distal tip. The cannula 206 can be used as the ground path and replace the body pad or other electrode, which may provide desirable impedance characteristics depending upon the desired clinical performance.
One method of delivering a large bore catheter in a single pass using the transseptal puncture system of the present invention may be as follows.
As will be appreciated by those of skill in the art, the GW and cannula can alternatively be simultaneously operated in monopolar mode; either the GW or cannula can be energized separately; or the GW and cannula can be operated in bipolar mode, depending upon the desired clinical performance.
Thus, referring to
The combination of the sheath 12 with the dilator 84 having the transseptal cannula 206 and GW 210 extending distally therefrom, is then drawn proximally from the superior vena cava while a curved section of the sheath, alone or in combination with a preset curve at the distal region of dilator 84 and or cannula 206, causes the tip of the cannula-GW combination to “drag” along the wall of the right atrium 86 and the septum 18, by proximal traction until the tip pops onto the fossa ovalis 92, as shown in
After the tip of the cannula-GW combination has been placed in the desired location against the fossa ovalis 92, RF energy is applied via the tip of the transseptal GW 210 to allow the GW 210 to pass through the septum into the LA. As previously described, RF energy may also be delivered via the distal end of the cannula 206 if desired. See
One medical technique is to confirm the presence of the tip of the transseptal GW 210 within the left atrium 16. Confirmation of such location of the tip of the transseptal GW 210 may be accomplished by monitoring the pressure sensed through a transseptal GW lumen or an annular lumen defined between the GW 210 and the inside surface of the cannula 206 central lumen to ensure that the measured pressure is within the expected range and has a waveform configuration typical of left atrial pressure. Alternatively, proper position within the left atrium 16 may be confirmed by analysis of oxygen saturation level of the blood drawn through an available lumen; i.e., aspirating fully oxygenated blood. Finally, visualization through fluoroscopy alone, or in combination with the use of dye, may also serve to confirm the presence of the tip of the transseptal cannula 206 and GW 210 in the left atrium 16.
After placing the transseptal cannula tip within the left atrium 16, the tip of the dilator 84 is advanced through the septum 18 and into the left atrium 16, as shown in
This application claims the priority benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 63/024,986, filed May 14, 2020, the entirety of which is hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
2056377 | Wappler | Oct 1936 | A |
4483338 | Bloom et al. | Nov 1984 | A |
4527560 | Masreliez | Jul 1985 | A |
4682596 | Bales et al. | Jul 1987 | A |
5021045 | Buckberg et al. | Jun 1991 | A |
5047026 | Rydell | Sep 1991 | A |
5190528 | Fonger et al. | Mar 1993 | A |
5221281 | Klicek | Jun 1993 | A |
5304171 | Gregory | Apr 1994 | A |
5348554 | Imran et al. | Sep 1994 | A |
5417687 | Nardella | May 1995 | A |
5431649 | Mulier et al. | Jul 1995 | A |
5676662 | Fleischhacker | Oct 1997 | A |
5676670 | Kim | Oct 1997 | A |
5797920 | Kim | Aug 1998 | A |
5871469 | Eggers | Feb 1999 | A |
5910129 | Koblish | Jun 1999 | A |
5941876 | Nardella | Aug 1999 | A |
5971968 | Tu et al. | Oct 1999 | A |
6004319 | Goble | Dec 1999 | A |
6012457 | Lesh | Jan 2000 | A |
6024740 | Lesh | Feb 2000 | A |
6056746 | Goble | May 2000 | A |
6074386 | Goble | Jun 2000 | A |
6102046 | Weinstein | Aug 2000 | A |
6146380 | Racz et al. | Nov 2000 | A |
6190353 | Makower et al. | Feb 2001 | B1 |
6193717 | Ouchi | Feb 2001 | B1 |
6231546 | Milo et al. | May 2001 | B1 |
6251107 | Schaer | Jun 2001 | B1 |
6391005 | Lum | May 2002 | B1 |
6475226 | Belef et al. | Nov 2002 | B1 |
6529756 | Phan | Mar 2003 | B1 |
6544230 | Flaherty et al. | Apr 2003 | B1 |
6565555 | Ryan et al. | May 2003 | B1 |
6565562 | Shah et al. | May 2003 | B1 |
6602248 | Sharps | Aug 2003 | B1 |
6645199 | Jenkins | Nov 2003 | B1 |
6650923 | Lesh et al. | Nov 2003 | B1 |
6723094 | Desinger | Apr 2004 | B1 |
6936024 | Houser | Aug 2005 | B1 |
7048733 | Hartley et al. | May 2006 | B2 |
7070596 | Woloszko | Jul 2006 | B1 |
7112197 | Hartley et al. | Sep 2006 | B2 |
7150747 | McDonald | Dec 2006 | B1 |
7194294 | Panescu et al. | Mar 2007 | B2 |
7229437 | Johnson | Jun 2007 | B2 |
7270662 | Visram et al. | Sep 2007 | B2 |
7824406 | Wang et al. | Nov 2010 | B2 |
7918851 | Webster, Jr. et al. | Apr 2011 | B2 |
7947040 | Davies et al. | May 2011 | B2 |
8092450 | Davies et al. | Jan 2012 | B2 |
8192425 | Mirza et al. | Jun 2012 | B2 |
8235985 | Saadat et al. | Aug 2012 | B2 |
8457714 | Shachar et al. | Jun 2013 | B2 |
8500768 | Cohen | Aug 2013 | B2 |
8679107 | Mirza et al. | Mar 2014 | B2 |
8834384 | Krishnan | Sep 2014 | B2 |
8882697 | Celermajer | Nov 2014 | B2 |
8992556 | Chanduszko et al. | Mar 2015 | B2 |
9095350 | Condie et al. | Aug 2015 | B2 |
9179932 | Davies et al. | Nov 2015 | B2 |
9351713 | Hancock | May 2016 | B2 |
9415188 | He et al. | Aug 2016 | B2 |
9504398 | Krishnan | Nov 2016 | B2 |
9510900 | Abou-Marie et al. | Dec 2016 | B2 |
9585692 | Kurth et al. | Mar 2017 | B2 |
9597146 | Davies et al. | Mar 2017 | B2 |
10166070 | Davies et al. | Jan 2019 | B2 |
10172632 | Morero et al. | Jan 2019 | B2 |
10183151 | Alvarez et al. | Jan 2019 | B2 |
10485569 | Lenker et al. | Nov 2019 | B2 |
10493259 | Urbanski et al. | Dec 2019 | B2 |
10610297 | Leung et al. | Apr 2020 | B2 |
10631915 | Cosman | Apr 2020 | B1 |
10639060 | Vardi et al. | May 2020 | B2 |
10716920 | Kurth et al. | Jul 2020 | B2 |
10820925 | Urbanski et al. | Nov 2020 | B2 |
10856902 | Leeflang et al. | Dec 2020 | B2 |
11007016 | Kusumoto | May 2021 | B2 |
11172984 | Sharma et al. | Nov 2021 | B2 |
11583312 | Howard et al. | Feb 2023 | B2 |
11751905 | Howard et al. | Sep 2023 | B2 |
11819241 | Howard et al. | Nov 2023 | B2 |
20010056280 | Underwood | Dec 2001 | A1 |
20020058905 | Madrid et al. | May 2002 | A1 |
20020095152 | Ciarrocca | Jul 2002 | A1 |
20020120259 | Lettice | Aug 2002 | A1 |
20020177765 | Bowe | Nov 2002 | A1 |
20020193781 | Loeb | Dec 2002 | A1 |
20030009164 | Woloszko | Jan 2003 | A1 |
20030083613 | Schaer | May 2003 | A1 |
20030088245 | Woloszko | May 2003 | A1 |
20030109809 | Jen et al. | Jun 2003 | A1 |
20030114833 | Thompson | Jun 2003 | A1 |
20030163153 | Scheib | Aug 2003 | A1 |
20040082860 | Haissaguerre | Apr 2004 | A1 |
20040133113 | Krishnan | Jul 2004 | A1 |
20040143261 | Hartley et al. | Jul 2004 | A1 |
20040143262 | Visram et al. | Jul 2004 | A1 |
20040167509 | Taimisto | Aug 2004 | A1 |
20040186469 | Woloszko | Sep 2004 | A1 |
20040220461 | Schwartz | Nov 2004 | A1 |
20040220462 | Schwartz | Nov 2004 | A1 |
20050033288 | Auth et al. | Feb 2005 | A1 |
20050065498 | McFerran | Mar 2005 | A1 |
20050149097 | Regnell et al. | Jul 2005 | A1 |
20050154386 | West et al. | Jul 2005 | A1 |
20050171478 | Selmon et al. | Aug 2005 | A1 |
20050215994 | Solomon | Sep 2005 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060079873 | Scopton | Apr 2006 | A1 |
20060178666 | Cosman et al. | Aug 2006 | A1 |
20060241583 | Malecki et al. | Oct 2006 | A1 |
20060287650 | Cao | Dec 2006 | A1 |
20070016182 | Lipson | Jan 2007 | A1 |
20070073389 | Bolduc et al. | Mar 2007 | A1 |
20080119846 | Rioux | May 2008 | A1 |
20080140073 | Schwartz | Jun 2008 | A1 |
20080154259 | Gough | Jun 2008 | A1 |
20080208184 | Davies | Aug 2008 | A1 |
20080215085 | Whisenant | Sep 2008 | A1 |
20090005774 | Fernald | Jan 2009 | A1 |
20090012517 | de la Rama et al. | Jan 2009 | A1 |
20090093803 | Herrin | Apr 2009 | A1 |
20090099555 | Viohl | Apr 2009 | A1 |
20100191142 | Paul et al. | Jul 2010 | A1 |
20110112564 | Wolf | May 2011 | A1 |
20110166519 | Nguyen | Jul 2011 | A1 |
20110224666 | Davies et al. | Sep 2011 | A1 |
20120232546 | Mirza et al. | Sep 2012 | A1 |
20130046305 | Davies | Feb 2013 | A1 |
20130317528 | Anderson et al. | Nov 2013 | A1 |
20140039492 | Long | Feb 2014 | A1 |
20140066917 | Cosman, Jr. | Mar 2014 | A1 |
20140100561 | Biadillah | Apr 2014 | A1 |
20140107644 | Falwell et al. | Apr 2014 | A1 |
20140121658 | Cosman, Jr. | May 2014 | A1 |
20140142607 | Cage et al. | May 2014 | A1 |
20140206987 | Urbanski et al. | Jul 2014 | A1 |
20140228841 | Davies | Aug 2014 | A1 |
20140364844 | Van Wyk | Dec 2014 | A1 |
20150141978 | Subramaniam et al. | May 2015 | A1 |
20150157353 | Lenker et al. | Jun 2015 | A1 |
20150173827 | Bloom | Jun 2015 | A1 |
20150182255 | Shivkumar | Jul 2015 | A1 |
20150223866 | Buelna | Aug 2015 | A1 |
20150265337 | Bloom | Sep 2015 | A1 |
20150265344 | Aktas et al. | Sep 2015 | A1 |
20150297246 | Patel | Oct 2015 | A1 |
20160045219 | Guala et al. | Feb 2016 | A1 |
20160235469 | Prisco | Aug 2016 | A1 |
20160262795 | Urbanski et al. | Sep 2016 | A1 |
20160374751 | Davies | Dec 2016 | A1 |
20170071667 | Leung | Mar 2017 | A1 |
20170135559 | Horrisberger et al. | May 2017 | A1 |
20170348049 | Vrba | Dec 2017 | A1 |
20170360498 | Davies et al. | Dec 2017 | A1 |
20180028258 | Zamarripa et al. | Feb 2018 | A1 |
20180064415 | Zhai et al. | Mar 2018 | A1 |
20180064915 | Kurth et al. | Mar 2018 | A1 |
20180070982 | Kimmel et al. | Mar 2018 | A1 |
20180133460 | Townley et al. | May 2018 | A1 |
20180146839 | Friedlander | May 2018 | A1 |
20180263658 | Drasler | Sep 2018 | A1 |
20180289388 | Lenker | Oct 2018 | A1 |
20180333162 | Saab | Nov 2018 | A1 |
20190125422 | Babkin et al. | May 2019 | A1 |
20190134349 | Cohn et al. | May 2019 | A1 |
20190274581 | Mosesov | Sep 2019 | A1 |
20190336198 | Viswanathan et al. | Nov 2019 | A1 |
20190374254 | Arevalos | Dec 2019 | A1 |
20190374281 | Davies | Dec 2019 | A1 |
20200008869 | Byrd | Jan 2020 | A1 |
20200038091 | Cao | Feb 2020 | A1 |
20200060710 | Urbanski et al. | Feb 2020 | A1 |
20200196908 | Ben-Haim et al. | Jun 2020 | A1 |
20200352647 | Davies | Nov 2020 | A1 |
20210038892 | Velasco Valcke | Feb 2021 | A1 |
20210068892 | Urbanski | Mar 2021 | A1 |
20210077419 | Buelna | Mar 2021 | A1 |
20210121227 | Davies et al. | Apr 2021 | A1 |
20210353354 | Schuler et al. | Nov 2021 | A1 |
20210353356 | Schuler et al. | Nov 2021 | A1 |
20210401483 | Highsmith et al. | Dec 2021 | A1 |
20220061884 | Howard et al. | Mar 2022 | A1 |
20220061909 | Howard et al. | Mar 2022 | A1 |
20220061911 | Howard et al. | Mar 2022 | A1 |
20220110577 | Highsmith et al. | Apr 2022 | A1 |
20220354533 | Lenker | Nov 2022 | A1 |
20230093231 | Howard et al. | Mar 2023 | A1 |
Number | Date | Country |
---|---|---|
2291901 | Sep 1998 | CN |
105193476 | Dec 2015 | CN |
2037812 | Mar 2009 | EP |
WO2018163899 | Sep 2018 | JP |
WO 2002058780 | Aug 2002 | WO |
WO 2005046487 | May 2005 | WO |
WO 2008008796 | Jan 2008 | WO |
WO 2013101632 | Jul 2013 | WO |
WO 2014089373 | Jun 2014 | WO |
WO 2018165277 | Sep 2018 | WO |
WO 2021014316 | Jan 2021 | WO |
WO 2021231465 | Nov 2021 | WO |
WO 2022046777 | Mar 2022 | WO |
Entry |
---|
Clinical Analysis of RF Transseptal Puncture, NRG Transseptal Needle, USA, Canada, Baylis Medical Company, Inc., 2016. |
International Search Report and Written Opinion, Application No. PCT/US2021/031827, dated Oct. 20, 2021. |
International Search Report and Written Opinion in corresponding International Patent Application No. PCT/US2021/047361, mailed Jan. 27, 2022, in 10 pages. |
U.S. Appl. No. 16/896,582, filed Jun. 9, 2020, Transseptal Crossing System for Single Pass Large Bore Access. |
U.S. Appl. No. 16/896,604, filed Jun. 9, 2020, Tubular Large Bore Transseptal Crossing Sheath. |
U.S. Appl. No. 16/896,648, filed Jun. 9, 2020, Method for Single Pass Large Bore Transseptal Crossing. |
Number | Date | Country | |
---|---|---|---|
20210353355 A1 | Nov 2021 | US |
Number | Date | Country | |
---|---|---|---|
63024986 | May 2020 | US |